Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/59586
Genomic profile of breast cancer: cost effectiveness analysis from the Spanish National Healthcare System perspective.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Cost
effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was 7100, 6380 and 4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost
effective from year 7 versus online algorithm (lifetime: 1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost
effective versus online algorithm.
effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was 7100, 6380 and 4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost
effective from year 7 versus online algorithm (lifetime: 1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost
effective versus online algorithm.
Matèries (anglès)
Citació
Citació
SEGUÍ, Miquel a., CRESPO, Carlos, CORTÉS, J., LLUCH HERNÁNDEZ, Ana, BROSA, Max, BECERRA, Victor, CHIAVENNA, S. m., GRACIA, A.. Genomic profile of breast cancer: cost effectiveness analysis from the Spanish National Healthcare System perspective.. _Expert Review of Pharmacoeconomics & Outcomes Research_. 2014. Vol. 14, núm. 6, pàgs. 889-899. [consulta: 24 de gener de 2026]. ISSN: 1473-7167. [Disponible a: https://hdl.handle.net/2445/59586]